My application for ethics was deferred because the reviewers said that administering Doxorubucin via an i.p injection will cause blistering and that it should be given i.v, however, every paper that I have read administers Doxorubicin i.p. I was just wondering if anyone has any information/articles that can substantiate and motivate why I am giving the injection i.p. All the papers I had read give the injections intraperitoneally, however, they do not state whether there were any negative effects, and this is what concerns the ethics committee. Are there advantages and disadvantages to given the drug iv vs ip? Thank you!

More Toni Leigh Goldswain's questions See All
Similar questions and discussions